Domestic & International
Dragon Pharma, Europe
Superdrol Inj
Injection · 40 mg/ml · 10 ml
$72.00
Compound ID
Methyldrostanolone
Dosage
40–80 mg/week
Concentration
40 mg/mL
Form
10 mL Multi-Dose Vial
Half-life
8–12 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma Superdrol Inj 40mg/mL — Injectable Methyldrostanolone for Maximum Anabolic Intensity with Reduced Hepatic Burden
Dragon Pharma Superdrol Inj 40mg/mL represents a revolutionary evolution of one of the most aggressively potent anabolic agents ever synthesized, translating the legendary mass-building power of Methyldrostanolone into an injectable format that fundamentally alters the risk-to-reward calculus. While oral Superdrol has long been revered for its ability to produce dramatic dry hypertrophy and explosive strength surges, its notorious hepatotoxicity has historically restricted cycle duration and dosing latitude.
The injectable formulation bypasses first-pass hepatic metabolism, dramatically reducing liver enzyme stress while delivering the same ultra-high anabolic payload directly into systemic circulation. Each milliliter of Dragon Pharma's oil-based solution provides precisely 40mg of Methyldrostanolone, with independent third-party verification confirming an actual potency of 45.23mg per milliliter—a substantial overage that ensures users receive the full intended pharmacological impact.
For advanced athletes who refuse to compromise on results but demand a more sophisticated delivery mechanism for this formidable compound, this formulation offers a verified, high-potency pathway to extreme physiological transformation.
What is Dragon Pharma Superdrol Inj 40?
Superdrol Inj 40 is a sterile oil-based injectable solution containing Methyldrostanolone, a synthetic anabolic-androgenic steroid structurally derived from Drostanolone (Masteron) through the addition of a 17-alpha-methyl group. This C17-aa modification historically enabled oral bioavailability by resisting hepatic degradation, but in the injectable format, the compound enters the bloodstream directly via intramuscular administration, circumventing the portal circulation and first-pass liver metabolism that accounts for the majority of oral Superdrol's hepatotoxic burden.
The compound retains its complete non-aromatizing, non-progestogenic character, meaning it cannot convert to estrogen or activate progesterone receptors. Its anabolic rating is among the highest of any AAS, producing rapid, substantial gains in lean contractile tissue and neuromuscular power. Dragon Pharma's 40mg per milliliter concentration supports convenient daily injection volumes, while the oil carrier ensures sustained release from the depot site.
The verified 45.23mg per milliliter analytical result demonstrates manufacturing precision that eliminates the underdosing and contamination risks endemic to unverified sources.
Key Benefits / Effects
- Significantly Reduced Hepatotoxicity: By bypassing first-pass hepatic metabolism, the injectable format places markedly less oxidative stress on liver enzyme systems than oral C17-aa tablets, potentially supporting safer dosing and slightly extended protocols under proper monitoring.
- Rapid Dry Hypertrophy: Users consistently report 10–15 pounds of dense, contractile lean tissue within a 4–6 week cycle, characterized by zero subcutaneous water retention and a distinctly hard, grainy aesthetic.
- Explosive Neuromuscular Strength: Core lift performance frequently escalates by 20–30% within the first 5–7 days, enabling aggressive progressive overload and shattering previous training plateaus.
- Extreme Muscular Density & Vascularity: The non-aromatizing nature combined with increased hematocrit and nutrient partitioning produces dramatic vein prominence, muscle separation, and a carved, three-dimensional appearance.
- Intense Intramuscular Pumps: Enhanced glycogen supercompensation and blood volume create prolonged, skin-splitting pumps during training that many users describe as comparable to or exceeding those from dedicated pump agents.
- Versatile Cycle Positioning: Functions effectively as both a frontloaded kickstarter to ignite long-ester bulking cycles and as a late-stage finisher to add final hardness and density before competition or photo shoots.
How Dragon Pharma Superdrol Inj 40 Works
The injectable formulation initiates its effects through intramuscular depot absorption, where the oil carrier gradually releases Methyldrostanolone into systemic circulation. Once in the bloodstream, the compound binds with ultra-high affinity to androgen receptors in skeletal myocytes, activating genomic transcription pathways that dramatically upregulate muscle protein synthesis, nitrogen retention, and satellite cell proliferation.
The 17-alpha-methyl structure prevents aromatase enzyme interaction and 5-alpha reductase conversion, ensuring that all receptor-mediated activity occurs within a purely androgenic environment devoid of estrogenic or progestogenic signaling. This creates an anabolic milieu where calories are partitioned aggressively toward contractile tissue and glycogen storage rather than adipose accumulation. The injectable route avoids the hepatic portal circulation, meaning the compound does not confront hepatocytes in concentrated form during initial absorption. Instead, it is distributed systemically to target tissues, with hepatic metabolism occurring gradually via standard oxidative pathways rather than the acute CYP450 overload characteristic of oral administration.
The net result is identical anabolic potency with a substantially improved hepatic safety margin, though the compound remains C17-alkylated and is not entirely liver-neutral.
Usage Information
Dragon Pharma Superdrol Inj 40 is supplied as a 40mg per milliliter oil-based injectable solution in multi-dose vials, designed exclusively for intramuscular administration by experienced male athletes. Due to Methyldrostanolone's short active half-life, daily injections are mandatory to maintain stable plasma concentrations and prevent pronounced hormonal fluctuation. Standard dosing begins at 20mg daily (0.5mL), with most intermediate users employing 40mg daily (1.0mL).
Advanced practitioners may cautiously explore 60mg daily (1.5mL), though side effect intensity escalates disproportionately beyond the 40mg threshold. Cycle duration must remain strictly limited to 4–6 weeks regardless of the reduced hepatic burden, as the compound's profound suppressive nature, cardiovascular stress, and lipid destruction impose hard physiological limits. Superdrol Inj 40 is almost never used as a standalone agent. For bulking kickstarts, it is paired with a long-acting testosterone base such as Testosterone Enanthate or Testabol 400 at 400–500mg weekly. For pre-contest finishing, it combines with Testosterone Propionate at conservative doses and potentially Helios for enhanced fat loss and grainy conditioning.
Comprehensive liver support with TUDCA, cardiovascular protection with lipid-modulating agents, and blood pressure management are mandatory. A robust Post-Cycle Therapy protocol must commence immediately upon cessation. Intramuscular injections should rotate among gluteal, deltoid, and vastus lateralis sites to prevent localized tissue irritation from daily administration.
Quality & Manufacturing
Dragon Pharma enforces uncompromising pharmaceutical manufacturing standards across all injectable production lines, with each Superdrol Inj 40 batch subjected to independent third-party laboratory analysis to verify sterility, active ingredient concentration, endotoxin levels, and heavy metal absence. Recent analytical testing conducted in October 2024 confirmed an actual Methyldrostanolone content of 45.23mg per milliliter—a meaningful 113% of the stated 40mg claim.
This intentional overage policy reflects Dragon Pharma's commitment to ensuring users receive at minimum the full pharmacological payload required for predictable outcomes, even accounting for minor degradation during storage or slight volumetric loss during drawing. In the high-potency injectable marketplace, where extreme compounds are frequently underdosed, degraded, or contaminated with bacterial endotoxins, this level of analytical transparency and batch consistency is essential. Athletes programming aggressive 4–6 week protocols can administer each injection with confidence that the volumetric dosing translates precisely to the intended milligram exposure.
Possible Side Effects / Safety Information
- Residual Hepatotoxicity: Despite bypassing first-pass metabolism, Methyldrostanolone remains C17-alpha alkylated and will elevate hepatic transaminases. Liver support with TUDCA at 750–1000mg daily and NAC at 1200–2400mg daily is mandatory; alcohol and acetaminophen are absolutely contraindicated.
- Catastrophic Dyslipidemia: Superdrol is notorious for aggressively depressing HDL cholesterol while elevating LDL cholesterol and triglycerides, creating a severely atherogenic lipid profile that demands dietary omega-3 supplementation and cardiovascular monitoring.
- Profound HPTA Suppression: The compound rapidly and completely shuts down endogenous testosterone production. A testosterone base during the cycle and comprehensive PCT with Clomiphene and Tamoxifen are non-negotiable.
- Extreme Blood Pressure Elevation: Increased hematocrit, vascular resistance, and potential fluid shifts can produce significant hypertension. Blood pressure should be monitored every 48–72 hours, and supportive measures such as Cialis or lifestyle modifications may be necessary.
- Debilitating Lethargy: Many users experience profound fatigue and motivational decline, particularly in weeks 3–6, likely stemming from hepatic stress, suppressed thyroid hormone conversion, and general physiological strain.
- Severe Appetite Suppression: Unlike traditional bulking agents, Superdrol frequently kills hunger, making it challenging to consume sufficient calories to maximize anabolic potential.
- Intense Androgenic Manifestations: Acne vulgaris, accelerated male pattern baldness in genetically predisposed individuals, increased terminal hair growth, and heightened aggression or irritability are commonly reported.
- Injection Site Reactions: Daily intramuscular administration increases the risk of post-injection pain, localized swelling, lipohypertrophy, and scar tissue accumulation without meticulous site rotation.
- Absolute Female Contraindication: The extreme androgenic potency produces rapid, irreversible virilization; female use is categorically prohibited under all circumstances.
Why Choose Dragon Pharma Superdrol Inj 40?
When manipulating a compound of such extreme potency, product integrity and delivery format become decisive variables separating transformative results from dangerous uncertainty. Dragon Pharma's verified 45.23mg per milliliter potency ensures that each 1.0mL daily injection delivers the full intended pharmacological payload, while the injectable format fundamentally reduces the hepatic burden that has historically limited oral Superdrol's practicality.
For advanced bodybuilders who demand the most aggressive short-cycle anabolic outcomes available—rapid dry mass accretion, explosive strength, and competition-grade density—but refuse to accept the catastrophic liver stress of oral C17-aa administration, this formulation provides a sophisticated, next-generation solution. The brand's commitment to analytical transparency, sterile manufacturing, and intentional potency overage transforms extreme physique enhancement from a reckless gamble into a calculated, informed protocol.
Product FAQ
Questions, answered
The injectable formulation bypasses the hepatic portal circulation, meaning Methyldrostanolone enters systemic blood flow directly from the intramuscular depot rather than passing through the liver in concentrated form during initial absorption. This dramatically reduces first-pass CYP450 enzyme overload and oxidative hepatocyte stress. While the compound remains structurally C17-alpha alkylated and will still elevate liver enzymes, clinical observation and user reports consistently indicate markedly milder transaminase elevations and improved liver enzyme recovery compared to equivalent oral doses. The injectable format does not eliminate hepatotoxicity entirely, but it shifts the risk profile favorably enough to make the compound more manageable for users who previously avoided oral Superdrol due to hepatic concerns.
Methyldrostanolone possesses a short active half-life, and maintaining stable plasma concentrations requires daily administration. Every-other-day injections would produce pronounced peak-trough fluctuations, leading to variable anabolic signaling, intensified side effects during peaks, and suboptimal receptor saturation during troughs. The daily injection schedule ensures consistent androgen receptor activation, stable nitrogen retention, and predictable strength and pump effects throughout the 24-hour period. While daily intramuscular administration demands diligent site rotation, it is the non-negotiable price of optimizing this compound's pharmacokinetics.
No. Methyldrostanolone rapidly and completely suppresses endogenous testosterone production, producing severe low-androgen symptoms including lethargy, libido collapse, erectile dysfunction, and depression when used without exogenous testosterone replacement. A testosterone base—typically 400–500mg weekly of Testosterone Enanthate, Cypionate, or a multi-ester blend like Testabol 400—is absolutely mandatory to maintain physiological androgen levels, preserve mental clarity, and support sexual function while Superdrol drives anabolic progress. Additionally, the appetite suppression associated with Superdrol makes standalone bulking nutritionally impractical.
For launching a mass-building cycle with explosive early gains, administer Superdrol Inj 40 at 20–40mg daily for the first 4 weeks alongside a long-acting testosterone base at 400–500mg weekly. This frontloading approach produces immediate visible changes while the testosterone esters build toward peak concentrations. An aromatase inhibitor should be available to manage estrogen from the testosterone component. After week 4, discontinue Superdrol and allow the testosterone base to sustain gains through the remaining 8–10 weeks of the cycle. This protocol captures Superdrol's rapid onset without extending its use beyond the safe physiological window.
For the final 3–4 weeks before a competition or photo shoot, Superdrol Inj 40 at 20–30mg daily adds exceptional density, hardness, and vascularity without water retention. Pair it with a low-dose testosterone propionate base at 50mg daily to minimize aromatization and fluid accumulation. Some advanced users add Helios or Clenbuterol for enhanced lipolysis and grainy conditioning. Because the injectable format reduces hepatic burden compared to oral administration, it may be slightly more feasible to integrate into late-stage protocols where liver enzymes are already stressed from preceding cycle components. Nonetheless, 4 weeks remains the absolute maximum for finisher use.
Superdrol frequently produces significant blood pressure elevation through multiple mechanisms including increased hematocrit, vascular tone changes, and potential fluid shifts. Monitoring should occur every 48–72 hours using a home cuff. Dietary sodium restriction, adequate hydration, and regular low-intensity cardiovascular exercise form the foundational approach. Tadalafil (Cialis) at 5–10mg daily is commonly employed both for its vasodilatory blood pressure-lowering effects and its ancillary benefits. If systolic pressure consistently exceeds 140mmHg or diastolic exceeds 90mmHg, dose reduction or cycle termination should be considered. Never combine Superdrol with other potent hypertensive agents without medical supervision.
Despite reduced hepatic stress compared to oral administration, comprehensive liver protection remains essential. Standard protocols include TUDCA at 750–1000mg daily and N-acetylcysteine (NAC) at 1200–2400mg daily. Additional support may include milk thistle, Liv-52, or glutathione precursors. Complete alcohol abstinence is mandatory throughout the cycle. Pre-cycle liver enzyme baselines (ALT, AST, GGT) must be established, with mid-cycle monitoring at week 2–3. If transaminases exceed three times the upper reference limit, immediate dose reduction or cycle termination is advised. Never stack with other hepatotoxic orals such as Methandienone or Winstrol.
Methyldrostanolone is among the most aggressively dyslipidemic compounds available, frequently producing dramatic HDL depression and significant LDL elevation within the first 2–3 weeks. Mitigation strategies include high-dose omega-3 fatty acid supplementation at 3–6g EPA/DHA daily, soluble fiber intake from psyllium husk or oats, antioxidant-rich foods, and complete avoidance of saturated fat excess and alcohol. Some advanced users incorporate statin therapy under medical supervision for extreme cases. Pre-cycle, mid-cycle (week 3), and post-cycle lipid panels are mandatory. If HDL crashes below 20mg/dL or LDL exceeds 200mg/dL, serious consideration should be given to cycle termination.
PCT must be aggressive due to the depth of suppression. Because the injectable ester is not long-acting, therapy can begin 3–5 days after the final injection. A comprehensive protocol includes Clomiphene Citrate at 50/50/25/25mg and Tamoxifen Citrate at 40/20/20/20mg over four weeks. For users who employed a testosterone base, PCT timing should account for the base ester clearance—Enanthate or Cypionate bases require approximately 14 days before SERM initiation. HCG at 500–1000IU every other day for the two weeks preceding PCT can prime testicular responsiveness. Blood work confirming recovered LH, FSH, and total testosterone should precede any subsequent cycle.
Yes, but meticulous planning is essential. Divide the body into six primary sites: left glute, right glute, left deltoid, right deltoid, left vastus lateralis, and right vastus lateralis. Inject into one site daily, returning to the same muscle no sooner than six days later. Use 25-gauge, 1.0-inch needles for deltoids and 1.5-inch needles for glutes and thighs. Inject slowly over 60–90 seconds to minimize tissue trauma. Massage the site gently post-injection and apply warm compresses if soreness develops. If a site becomes persistently irritated, swollen, or warm, skip it until fully resolved to prevent lipohypertrophy or sterile abscess formation.
Most users report noticeable increases in training aggression, vascularity, and intramuscular pumps within the first 3–5 days. Visible lean mass changes and strength breakthroughs typically consolidate by the end of week one, with maximal dry tissue accretion, density, and hardness appearing during weeks 2–4. The injectable format may produce a slightly smoother onset compared to oral tablets, with less acute "kick" but equally powerful cumulative effects by week two. Because gains are dry and non-estrogenic, scale weight increases of 10–15 pounds represent predominantly contractile tissue and glycogen rather than fluid.
No. This compound is explicitly reserved for advanced male athletes with extensive prior anabolic experience, multiple completed cycles, and thorough understanding of side-effect management, injection technique, and blood work interpretation. The extreme potency, daily injection requirement, profound suppression, aggressive lipid destruction, and residual hepatotoxicity create a risk profile that beginners are ill-equipped to recognize or manage. Novice users should develop their foundational understanding through milder, more forgiving compounds such as Testosterone-only cycles or conservative Turinabol protocols before considering Methyldrostanolone in any format.
Absolutely not. The extreme androgenic potency of Methyldrostanolone produces rapid, irreversible virilization even at micro-doses that would be imperceptible for male users. Female exposure would result in near-certain voice deepening, clitoral enlargement, facial and body hair growth, and menstrual cessation within days of initiation. There is no safe therapeutic window for women with this compound, and its use is categorically contraindicated under all circumstances.
